Rize Oncology (XCNQ:RIZE) Other Income (Expense) : C$0.01 Mil (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Rize Oncology Other Income (Expense)?

Rize Oncology's other income expense for the Rize Oncology's pretax income for the three months ended in Sep. 2024 was C$0.00 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.01 Mil.

Rize Oncology Other Income (Expense) Historical Data

The historical data trend for Rize Oncology's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rize Oncology Other Income (Expense) Chart

Rize Oncology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Other Income (Expense)

0.01

Rize Oncology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Income (Expense)	Get a 7-Day Free Trial											-	0.01	-	-	-

Rize Oncology Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.01 Mil.

Rize Oncology (XCNQ:RIZE) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Rize Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, X1X 1X1

Website

https://www.rizeoncology.com

Rize Oncology Inc is is a pharmaceutical company. The company is engaged in oncology, particularly soft tissue sarcoma, introduced by the recent exclusive licensing of STS-201, delivering small molecule targeting soft tissue sarcoma and other cancers.

Executives

William James Garner

10% Security Holder, Director

Rize Oncology Headlines

No Headlines